New Respirable and Fast Dissolving Itraconazole Dry Powder Composition for the Treatment of Invasive Pulmonary Aspergillosis
- 579 Downloads
Novel itraconazole (ITZ)-based dry powders for inhalation (DPI) were optimized for aerodynamic and dissolution properties and contained excipients that are acceptable for inhalation.
The DPI were produced by spray drying solutions. The drug content, crystallinity state, and morphological evaluation of the dry powders were determined by high performance liquid chromatography, powder X-ray diffraction, differential scanning calorimetry, and scanning electron microscopy, respectively. A particle size analysis was conducted using laser light scattering. The aerodynamic behaviors of the powders were characterized by impaction tests. ITZ dissolution rates were evaluated using a dissolution method adapted to inhaled products.
The DPI presented very high fine particle fractions that ranged from 46.9% to 67.0% of the nominal dose. The formulations showed very fast dissolution rates compared to unformulated crystalline ITZ with the possibility of modulating the dissolution rate by varying the quantity of phospholipids (PL) incorporated. ITZ remained amorphous while the mannitol was crystalline. The α, β and δ-mannitol polymorph ratios varied depending on the formulation compositions.
This formulation strategy could be an attractive alternative for treating invasive pulmonary aspergillosis. The ITZ and PL content are key characteristics because of their influence on the dissolution rate and aerosol performance.
KEY WORDSdry powder for inhalation (DPI) invasive aspergillosis itraconazole mannitol polymorphism
active pharmaceutical ingredient
dry powder(s) for inhalation
Food and Drug Administration
fine particle dose
fine particle fraction
International Center for Diffraction Data
minimal inhibitory concentration
multi-stage liquid impactor
modulated temperature differential scanning calorimetry
next generation impactor
particle size distribution
powder X-ray diffraction
reference intensity ratio
round per minute
scanning electron microscopy
- 6.Hoeben BJ, Burgess DS, McConville JT, Najvar LK, Talbert RL, Peters JI, Wiederhold NP, Frei BL, Graybill JR, Bocanegra R, Overhoff KA, Sinswat P, Johnston KP, Williams RO. In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2006;50:1552–4.PubMedCrossRefGoogle Scholar
- 7.Alvarez CA, Wiederhold NP, McConville JT, Peters JI, Najvar LK, Graybill JR, Coalson JJ, Talbert RL, Burgess DS, Bocanegra R, Johnston KP, Williams RO. Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis. J Infect. 2007;55:68–74.PubMedCrossRefGoogle Scholar
- 13.Bindu MB, Kusum B, Banji D. Novel strategies for poorly water soluble drugs. Int J Pharm Sci Rev Res. 2010;4:76–84.Google Scholar
- 31.Ostwald W. Studien uber die bildung und Umwandlung fester Korper. Z Phys Chem. 1897;22:289.Google Scholar
- 40.Berenguer J, Ali NM, Allende MC, Lee J, Garrett K, Battaglia S, Piscitelli SC, Rinaldi MG, Pizzo PA, Walsh TJ. Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma. Antimicrob Agents Chemother. 1994;38:1303–8.PubMedCrossRefGoogle Scholar
- 41.Pfaller MA, Messer SA, Hollis RJ, Jones RN. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother. 2002;46:1032–7.PubMedCrossRefGoogle Scholar
- 45.Mortensen KL, Johansen HK, Fuursted K, Knudsen JD, Gahrn-Hansen B, Jensen RH, Howard SJ, Arendrup MC. A prospective survey of Aspergillus spp. in respiratory tract samples: prevalence, clinical impact and antifungal susceptibility. Eur J Clin Microbiol Infect Dis. 2011;30:1355–63.PubMedCrossRefGoogle Scholar